These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 10485081)

  • 21. Sampling Optimization in Pharmacokinetic Bridging Studies: Example of the Use of Deferiprone in Children With β-Thalassemia.
    Bellanti F; Di Iorio VL; Danhof M; Della Pasqua O
    J Clin Pharmacol; 2016 Sep; 56(9):1094-103. PubMed ID: 26785826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estimation of pharmacokinetic parameters by orthogonal regression: comparison of four algorithms.
    Tod M; Aouimer A; Petitjean O
    Comput Methods Programs Biomed; 2002 Jan; 67(1):13-26. PubMed ID: 11750944
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimal sampling times for Bayesian estimation of the pharmacokinetic parameters of nortriptyline during therapeutic drug monitoring.
    Merlé Y; Mentré F
    J Pharmacokinet Biopharm; 1999 Feb; 27(1):85-101. PubMed ID: 10533699
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Robust designs in longitudinal studies accounting for parameter and model uncertainties - application to count data.
    Loingeville F; Nguyen TT; Riviere MK; Mentré F
    J Biopharm Stat; 2020; 30(1):31-45. PubMed ID: 31032703
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of using a robust optimality criterion in model based adaptive optimization.
    Strömberg EA; Hooker AC
    J Pharmacokinet Pharmacodyn; 2017 Aug; 44(4):317-324. PubMed ID: 28386710
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the pre-posterior distribution of optimized sampling times for the design of pharmacokinetic studies.
    Duffull SB; Graham G; Mengersen K; Eccleston J
    J Biopharm Stat; 2012; 22(1):16-29. PubMed ID: 22204524
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design and power of a population pharmacokinetic study.
    Lee PI
    Pharm Res; 2001 Jan; 18(1):75-82. PubMed ID: 11336356
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimal sampling schedule design for populations of patients.
    Tam VH; Preston SL; Drusano GL
    Antimicrob Agents Chemother; 2003 Sep; 47(9):2888-91. PubMed ID: 12936990
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimizing pharmacokinetic bridging studies in paediatric oncology using physiologically-based pharmacokinetic modelling: application to docetaxel.
    Thai HT; Mazuir F; Cartot-Cotton S; Veyrat-Follet C
    Br J Clin Pharmacol; 2015 Sep; 80(3):534-47. PubMed ID: 26095234
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients.
    Hennig S; Wainwright CE; Bell SC; Miller H; Friberg LE; Charles BG
    Clin Pharmacokinet; 2006; 45(11):1099-114. PubMed ID: 17048974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A note on population pharmacokinetic studies with a single sampling design.
    Narukawa M; Yafune A
    Ther Drug Monit; 2005 Apr; 27(2):111-5. PubMed ID: 15795638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A pragmatic approach to the design of population pharmacokinetic studies.
    Roy A; Ette EI
    AAPS J; 2005 Oct; 7(2):E408-20. PubMed ID: 16353920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimal population designs for PK models with serial sampling.
    Gagnon R; Leonov S
    J Biopharm Stat; 2005; 15(1):143-63. PubMed ID: 15702610
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stochastic optimization algorithms of a Bayesian design criterion for Bayesian parameter estimation of nonlinear regression models: application in pharmacokinetics.
    Merlé Y; Mentré F
    Math Biosci; 1997 Aug; 144(1):45-70. PubMed ID: 9232968
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design of experiments for the precise estimation of dose-response parameters: the Hill equation.
    Bezeau M; Endrenyi L
    J Theor Biol; 1986 Dec; 123(4):415-30. PubMed ID: 3657186
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A pharmacometric case study regarding the sensitivity of structural model parameter estimation to error in patient reported dosing times.
    Knights J; Rohatagi S
    J Pharmacokinet Pharmacodyn; 2015 Dec; 42(6):627-37. PubMed ID: 26209956
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population pharmacokinetics with a very small sample size.
    Mahmood I; Duan J
    Drug Metabol Drug Interact; 2009; 24(2-4):259-74. PubMed ID: 20408503
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimal experiment design for nonlinear models subject to large prior uncertainties.
    Walter E; Pronzato L
    Am J Physiol; 1987 Sep; 253(3 Pt 2):R530-4. PubMed ID: 3631311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimal design for multivariate response pharmacokinetic models.
    Gueorguieva I; Aarons L; Ogungbenro K; Jorga KM; Rodgers T; Rowland M
    J Pharmacokinet Pharmacodyn; 2006 Apr; 33(2):97-124. PubMed ID: 16550455
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An innovative phase I population pharmacokinetic approach to investigate the pharmacokinetics of an intranasal fentanyl spray in healthy subjects.
    Plock N; Facius A; Hartmann L; Baumann S; Nave R
    Int J Clin Pharmacol Ther; 2013 Jun; 51(6):495-508. PubMed ID: 23611571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.